113 related articles for article (PubMed ID: 22730705)
1. HER-2/neu oncogene and estrogen receptor expression in non small cell lung cancer patients.
Alerić I; Razumović JJ; Koprivica B
Med Pregl; 2012; 65(5-6):210-5. PubMed ID: 22730705
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
3. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma: pathologic and prognostic correlations.
Vargas SO; Leslie KO; Vacek PM; Socinski MA; Weaver DL
Cancer; 1998 Apr; 82(8):1495-500. PubMed ID: 9554526
[TBL] [Abstract][Full Text] [Related]
5. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.
Harpole DH; Herndon JE; Wolfe WG; Iglehart JD; Marks JR
Cancer Res; 1995 Jan; 55(1):51-6. PubMed ID: 7805040
[TBL] [Abstract][Full Text] [Related]
6. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers.
Wu CT; Chang YL; Shih JY; Lee YC
J Thorac Cardiovasc Surg; 2005 Oct; 130(4):979-86. PubMed ID: 16214508
[TBL] [Abstract][Full Text] [Related]
7. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
[TBL] [Abstract][Full Text] [Related]
8. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.
Yi ES; Harclerode D; Gondo M; Stephenson M; Brown RW; Younes M; Cagle PT
Mod Pathol; 1997 Feb; 10(2):142-8. PubMed ID: 9127320
[TBL] [Abstract][Full Text] [Related]
9. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
[TBL] [Abstract][Full Text] [Related]
10. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
11. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis.
Pirinen R; Leinonen T; Böhm J; Johansson R; Ropponen K; Kumpulainen E; Kosma VM
Hum Pathol; 2005 Jan; 36(1):44-50. PubMed ID: 15712181
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
Hommura F; Dosaka-Akita H; Mishina T; Nishi M; Kojima T; Hiroumi H; Ogura S; Shimizu M; Katoh H; Kawakami Y
Clin Cancer Res; 2000 Oct; 6(10):4073-81. PubMed ID: 11051259
[TBL] [Abstract][Full Text] [Related]
13. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
15. [Expression of ERCC1 mRNA and its impact on the prognosis of patients with non-small cell lung cancer].
Ma W; Li W; Gao M; Li XN
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):371-4. PubMed ID: 21875468
[TBL] [Abstract][Full Text] [Related]
16. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival.
Laudanski J; Chyczewski L; Niklińska WE; Kretowska M; Furman M; Sawicki B; Nikliński J
Neoplasma; 1999; 46(1):25-30. PubMed ID: 10355530
[TBL] [Abstract][Full Text] [Related]
17. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Turley H; Talks K; Pezzella F; Gatter KC; Harris AL
Br J Cancer; 2001 Sep; 85(6):881-90. PubMed ID: 11556841
[TBL] [Abstract][Full Text] [Related]
18. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
20. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival.
Skov BG; Fischer BM; Pappot H
Lung Cancer; 2008 Jan; 59(1):88-94. PubMed ID: 17905466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
